A Section 1b medical demo assessing the safety and pharmacological profile of DNL343, Denali Therapeutics’ investigational oral therapy, in adults with amyotrophic lateral sclerosis (ALS) has began dosing participants. The location is protected. The https:// ensures that you are connecting into the Formal Internet site Which any info you supply https://bobbys998fcr1.wikiconverse.com/user